The EFFECT Study: Probiotic and HMO Supplementation in Infants

Completed · Not applicable

Conditions studied: Infant Gut Microbiome

In brief

Lacto-N-tetraose (LNT) is a human milk oligosaccharide (HMO) present in human colostrum and milk. HMOs are largely undigestable and have no direct nutritive benefit to the infant, but act as a prebiotic substrate for beneficial bacteria (bifidobacteria, in particular) in the infant gut. Exclusively formula-fed infants lack HMOs in their diet in the absence of naturally occurring HMOs from breast milk. The proposed clinical study will evaluate the ability of a prebiotic supplement (LNT) to initiate intestinal colonization of a probiotic strain (B. infantis EVC001) in exclusively formula-fed infants. B. infantis EVC001 has been shown to be well-tolerated and safely consumed in breastfed infants. This study also aims to evaluate the safety and tolerability of LNT in different doses when consumed daily with B. infantis EVC001.

Key facts

Study ID

NCT03994315

Run by

Evolve BioSystems, Inc.

People needed

10

Starts

2019-09-12

Expected to finish

2020-03-13

Last updated by the study team

2020-07-09

Who can join

Age: any, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Infant is between 0 and 60 days of life at the time of enrollment
• Infant is exclusively formula-fed with caregiver intent to continue exclusive formula feeding for the duration of the study (at least 7 weeks)
• Infant is consuming cow's milk-based formula without probiotics
• Term infant, born >37 weeks gestation
• Infant is healthy and without medical complications
• Infant's caregivers are willing to refrain from feeding their infant breast milk, solid foods, and non-study probiotics prior to study completion

You may not qualify if…

• Infant was born with medical complications such as respiratory distress syndrome or birth defects
• Infant has any gastrointestinal tract abnormalities
• Infant has been diagnosed with failure to thrive
• Infant has taken oral or IV antibiotics or antifungals within 4 weeks of enrollment or during the Lead-in Period
• Infant is consuming partially hydrolyzed or extensively hydrolyzed infant formula because of gastrointestinal disturbance or gassiness/fussiness
• Infant has consumed any breast milk within 7 days of enrollment or during the Lead-in Period
• Infant has consumed any probiotics containing B. infantis since birth
• Infant has consumed any Bifidobacterium-containing probiotics within 2 weeks of enrollment or during the Lead-in Period
• Infant's caregivers plan to feed them any breast milk, solid foods, or non-study probiotics at any time throughout the duration of the study
• Infant was born in a multiple birth
• Infant lives in more than one location
• Any infant who the investigator feels is not an appropriate study participant

Where it is running

• Coastal Pediatric Research — Charleston, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.